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ABSTRACT 
 
In June 2013, the European Medicine Agency recommended limiting codeine use in 
paediatric patients, creating a void in managing moderate pain. We reviewed literature 
published in English (1985-June 2017) on the pharmacokinetic, pharmacodynamic and 
safety profile of ketorolac, a possible substitute for codeine and opioids, for treating 
moderate to severe pain. We found that gastrointestinal side effects were mainly reported 
with prolonged use, significant bleeding was reported in adenotonsillectomies and adverse 
renal effects appeared to be limited to patients with specific coexisting risk factors. 
Conclusion. The short-term use of ketorolac appears to be safe for children in many 
situations.  
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Key notes 
 In June 2013, the European Medicine Agency advice limiting codeine use in paediatric 
patients created a void in managing moderate pain. 
 We reviewed literature published in English from 1985 to June 2017 on the 
pharmacokinetic, pharmacodynamic and safety profile of ketorolac, a possible substitute 
for codeine and opioids. 
 The short-term use of ketorolac in children appears to be safe, but prolonged use or 
coexisting risk factors can increase the risk of side effects.  
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Abbreviations 
EMA, European Medicine Agency; FDA, US Food and Drug Administration; NSAIDs, 
nonsteroidal anti-inflammatory drugs  
 
INTRODUCTION  
 
Pain is a common symptom in children attending emergency departments and ambulatory 
settings (1). Drugs such as paracetamol and ibuprofen are commonly and safely used in the 
management of mild pain (2). Treatment options for moderate pain are limited, as 
paracetamol or ibuprofen may not be effective and major opioids may be considered 
excessive or inconvenient in terms of side effects (1). In June 2013 the European Medicine 
Agency (EMA) recommended that codeine should not be used for postoperative pain control 
in children undergoing adenoidectomies or tonsillectomies for obstructive sleep apnoea and 
restricted the use of this drug in the paediatric population. This created a void in the 
management of moderate pain (3). Codeine is no longer recommended due to low efficacy 
in poor metabolisers and possible life-threatening events in    ultra-rapid metabolisers (3,4). 
There is some evidence that tramadol could be safe and effective in treating moderate pain 
in paediatric inpatients and outpatients (4). Even though, tramadol is a prodrug, some 
experts have suggested limiting its use in monitored settings for children with specific risk 
factors for respiratory depression, while waiting for more safety data (4). As a matter of fact, 
in April 2017 the US Food and Drug Administration (FDA) banned the use of codeine and 
tramadol in children under 12 years of age and recommended that breastfeeding mothers 
did not take these drugs due to the risk of serious adverse reactions in breastfed infants. In 
addition, the FDA warned against using codeine and tramadol for patients aged 12 to 18 
years if they had a  history of obesity, obstructive sleep apnoea or severe lung disease. In 
particular, neither codeine nor tramadol should be given to children or adolescents as pain 
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medication after a tonsillectomy or adenoidectomy (5). Complying with these 
recommendations has led to changes in clinical practice and in treatment strategies to 
assure that adequate pain control could be provided for paediatric patients (3-5).  
Ketorolac is a drug that could be considered for the treatment of moderate to severe pain. 
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the short-term, up to 
a maximum of five days, management of moderate to severe acute pain in adults (6). 
Ketorolac exerts its analgesic, anti-inflammatory and antipyretic actions by inhibiting cyclo-
oxygenase, resulting in a reduction in the synthesis of prostaglandins, thromboxanes and 
prostacyclin (7). Presently, it is not indicated for paediatric use (6), except for moderate to 
severe post-operative pain, according to the British National Formulary, but a growing 
number of reports in the literature suggest that it provides good efficacy and safety when it is 
properly used in other settings. The aim of this review was to examine the available 
evidence on the pharmacokinetic, pharmacodynamics, efficacy and safety profile of 
ketorolac in children and adolescents and to discuss its possible use as an alternative to 
tramadol and opioids for managing moderate to severe acute pain. 
 
Search strategy and selection criteria  
This was a narrative review. The Cochrane Library, Medline, PubMed and relevant specialist 
journals were searched from 1985 to June 2017. We searched for the combination of 
ketorolac and the following words and phrases: paediatric, children, infants, 
pharmacokinetics, metabolism, sublingual administration, intranasal administration, post-
operative pain, safety, toxicity, bleeding, gastrointestinal bleeding and kidney injury. In 
addition we searched for pain management and children. 
Publications from the past 30 years were selected with an emphasis on the past five years, 
but commonly referenced, relevant and influential older publications were not excluded. The 
reference lists in the papers identified by our search strategy were also searched. Searches 
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were restricted to publications in English. Randomised controlled trials, observational 
studies, retrospective studies, meta-analyses and case reports were included.  Abstracts 
were excluded. Book chapters, guidelines, review articles and editorials in English were also 
included, as well as online English resources such as Medscape and UpToDate, because 
they provided comprehensive overviews that met the scope of this review.  
 
Elements of pharmacokinetics 
Absorption  
Ketorolac tromethamine is well absorbed when administered either orally or via the 
intramuscular route. The maximal plasma concentration is attained between 20 and 60 
minutes (8), which is faster for the intramuscular than the oral route (9). For the intravenous 
route, the time to peak concentration is 1-3 minutes (10). The systemic bioavailability of the 
oral and intramuscular administration is 100% ±20 and 100% ±22%, respectively (10). Food 
intake delays, but does not reduce, ketorolac absorption when administered orally (9). When 
ketorolac is administered as tablets, the rate at which the tablets dissolve is a limitation of 
the absorption velocity and the onset of action (11). The use of fast dissolving tablets 
improves the dissolution and absorption rate (11).  Sublingual administration may have 
several advantages, such as improved bioavailability and more comfortable administration 
compared to the intravenous route. Children from the age of six years and above have been 
shown to be able to take sublingual drugs with adequate support from nurses (12). Ketorolac 
is absorbed more rapidly after sublingual than intramuscular administration: the sublingual 
route takes about half an hour to achieve an increase in peak concentration, and a reduction 
in the time to attain this, compared to one hour for the intramuscular route (Figure 1 and 
Table 1). In addition, the extent of absorption has been shown to be similar for both of these 
routes, with no important change in the area under the curve and elimination half-life, and 
there appears to be no difference in the duration of the analgesic activity of the drug (13).  
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The intranasal formulation provides several benefits, such as rapid absorption across the 
nasal mucosa and ease of administration (14). Another study showed that administering 
15mg of ketorolac (weight <50kg) or 30mg (weight >50kg) by the intranasal route using a 
metered spray resulted in a rapid increase in plasma concentration. The mean time to peak 
concentration using the intranasal route was 52 minutes, with a standard deviation of six 
minutes. A target concentration of 0.37mg/L in the effect compartment was achieved within 
30 minutes and remained above that target for 10 hours (15). An analysis of the 
postoperative analgesia provided by ketorolac in adults showed an estimated effect 
compartment with 50% effective concentration of 0.37mg/L. The pharmacokinetics of 
intranasal ketorolac has been shown to be similar in adolescents and adults, assuming the 
use of the same nasal administration device. Intranasal ketorolac may be a useful 
therapeutic alternative to intravenous injections in adolescents, because the plasma 
concentrations attained with the device are likely to be analgesic (15). Most of the ketorolac 
administered intranasally is deposited in the nasal cavity and pharynx, with less than 20% in 
the oesophagus and stomach and less than 0.5% in the lungs (6,16). The reduction in the 
time to achieve a maximum concentration did not differ significantly between a single dose of 
30mg intranasal ketorolac and a single dose of 30mg intramuscular ketorolac in healthy 
volunteers, while the systemic availability of the intranasal ketorolac was lower than the 
intramuscular ketorolac. Ketorolac is rapidly and well absorbed via the intranasal route, with 
a reduced bioavailability compared to the intramuscular route. Intranasal administration, 
therefore, offers a therapeutic alternative to other routes of administration in different clinical 
settings (16).  
Distribution  
After intravenous administration, the volume of distribution at a steady state was 113 
±33mL/kg (17). The body weight normalised paediatric pharmacokinetics variables for 
children aged one to 16 years are similar to adult values (10,17,18). On the other hand, 
studies in neonates and young infants indicated a volume of distribution at a steady state of 
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290mL/kg, which was greater than that of children older than one year and adults (19,20). 
Ketorolac has been shown to be extensively bound (>99%) to plasma proteins and had a 
volume of distribution of 0.1 to 0.3L/kg in healthy young volunteers and 0.36L/kg in children 
comparable with those of other nonsteroidal anti-inflammatory drugs (NSAIDs) (8). There is 
evidence that ketorolac does not readily penetrate the central nervous system in children, 
with less than 0.05% of the ketorolac plasmatic concentrations found in the cerebrospinal 
fluid (21). Higher ketorolac cerebrospinal fluid concentrations have been reported in younger 
children, particularly those under two years of age (21). 
 
Metabolism and elimination 
The elimination clearance has been reported to be 0.57 ±0.17mL/min/kg in children aged 
one year and above, which was similar in adults (17,18). The clearance is higher in 
neonates and infants, reaching values of 1.52mL/min/kg (19-21). Ketorolac has an 
elimination half-life of about 4-6 hours (8). In order to maintain ketorolac plasma levels that 
were consistent with adult analgesic concentrations in most infants, a dosing regimen of a 
bolus every four to six hours would be reasonable (19,22). Ketorolac is extensively 
metabolised in the liver to inactive or mainly inactive metabolites. The metabolic products 
are hydroxylated and conjugated forms of the parent drug. The major metabolite of ketorolac 
is the acyl-glucuronide (23). The other important ketorolac metabolite is the p-hydroxyl-
ketorolac, presenting 20% of the anti-inflammatory activity and 1% of the analgesic activity of 
ketorolac (8). The principal route of the elimination of ketorolac and its metabolites is the 
renal route. About 92% of a given dose is found in the urine, approximately 40% as 
metabolites and 60% as unchanged ketorolac. About 6% of the dose is excreted in the 
faeces (6,24) (Table 2).  
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Stereoselective pharmacokinetics 
Ketorolac is a chiral substance with (S)-enantiomers and (R)-enantiomers and in vitro and 
animals studies have suggested that its pharmacological activity is mainly related to (S)-
ketorolac (25-27). Hamunemn et al showed that the clearance, volume of distribution and 
elimination half-life were higher for (S)-enantiomers than (R)-enantiomers (28). The volume 
of distribution at the steady state and elimination half-life of the (S)-enantiomer were higher 
in children than in adolescents and adults, but the clearance was similar (28). The 
pharmacokinetics of the (R)-enantiomer was essentially unaffected by age (28). Therefore, 
children, adolescents and adults require similar maintenance doses (28). Moreover, infants 
aged 6-18 months showed rapid elimination of the analgesic (S)-enantiomer and, therefore, 
in this age group, shorter dose intervals to maintain (S)-enantiomer concentrations might 
seem indicated, but will result in (R)-enantiomer accumulation with unknown clinical 
implications (22,23,29). In conclusion, the (S)-enantiomer has been shown to have greater 
analgesic and anti-inflammatory activity than the (R)-enantiomer. 
 
Elements of pharmacodynamics 
Ketorolac is an NSAID and exerts its analgesic, anti-inflammatory and antipyretic actions by 
inhibiting cyclo-oxygenase, resulting in a reduction in the synthesis of prostaglandins, 
thromboxanes and prostacyclin (7). The mechanisms by which ketorolac may exert a central 
effect are still unclear. Ketorolac does not directly bind to mu-opiod, kappa-opiod or delta-
opioid receptors, but it could indirectly activate opioid receptors by inducing the release of 
endogenous opioids (30).  It has also been reported that ketorolac is associated with 
mitochondrial calcium release, local nitric oxide synthesis and interaction with the 
cannabinoid receptor and all these processes may be involved in its analgesic effect (30). In 
several clinical trials, ketorolac, administered by different routes, produced analgesia to a 
similar extent as morphine and other opioids, but was not associated with sedative or 
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anxiolytic effects and did not have any effects on gut motility (7,29,30). When ketorolac was 
co-administered with morphine, it produced a higher analgesic effect than that obtained with 
either drug alone or together (30).                                               The pharmacological drug 
interactions of ketorolac with concomitant treatments (14) are presented in Table 3.  
There is no evidence in animal or human studies that ketorolac induces or inhibits any of the 
hepatic enzymes that are involved in its metabolism or that of other drugs (6).  
 
Side effects 
The most important adverse effects of ketorolac are bleeding and gastritis and these 
typically occur after repeated doses (30). The gastrointestinal side effects of ketorolac and 
other NSAIDs are due to the inhibition of gastric mucosal prostaglandin synthesis with 
subsequent mucosal damage caused by stomach acid. The risk of upper gastrointestinal 
bleeding increases with the use of long-acting forms of NSAIDs and seems to be higher with 
ketorolac when compared with ibuprofen or other NSAIDs, such as indomethacin and 
diclofenac (31,32). In adults, the mucosal injury caused by ketorolac, when it is administered 
at doses of 10 to 30mg four times daily, has been reported to be remarkably less than that 
caused by 650mg aspirin administered four times a day (33). Due to the possible increase in 
the risk of bleeding events, many surgeons may prefer not to use ketorolac perioperatively. 
In a retrospective analysis of 1,451 children that had undergone neurosurgical procedures, 
including 955 who received perioperative ketorolac, there was no significant association 
between clinically significant bleeding events or radiographic haemorrhages and the 
perioperative administration of ketorolac (34). Although, several reports have associated an 
increased incidence of bleeding after tonsillectomies with the perioperative use of ketorolac, 
a retrospective study of 310 children who underwent tonsillectomy found that using ketorolac 
did not increase the incidence of post-tonsillectomy haemorrhage and was associated with a 
shorter length of hospital stay (35). Chan et al (36) showed that ketorolac could be used 
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safely for tonsillectomies in children, but not in adults. On the other hand, a prospective 
study on 96 children receiving intravenous morphine or ketorolac showed that patients who 
received ketorolac had more major bleeding requiring intervention and more bleeding 
episodes in the first 24 hours after surgery, but no greater overall incidence of bleeding 
when compared to the morphine treated subjects (37). Although, it is true that bleeding time 
seems to be increased, even after a single dose of ketorolac (38), clinically important 
bleeding is usually not reported (39). In another retrospective review conducted on 221 
children who underwent operative fracture care, including 169 who 
received ketorolac perioperatively and 52 who did not receive the drug, there was no 
difference in overall complication rates and the need for blood transfusion between the two 
groups (40). Furthermore, in a retrospective study on 208 children that underwent spine 
surgery, the postoperative use of ketorolac did not significantly increase complications, 
including transfusions and reoperations (41).  
As with any other NSAID, ketorolac inhibits the synthesis of prostaglandin and is mainly 
excreted by the kidney, making the risk of adverse renal effects relevant. In a retrospective 
analysis of 1,015 children over a 10-year period, NSAIDs accounted for 2.7% of acute 
kidney injuries (42). A retrospective case-control study showed that the concomitant 
administration of aspirin and ketorolac could increase renal morbidity in young infants of less 
than six months of age after cardiac surgery (43). There are single case reports of acute 
renal failure associated with ketorolac administration, but it is not commonly seen unless risk 
factors are present. For this reason, the use of ketorolac should be avoided in patients with 
risk factors for nephrotoxicity, such as hypo-perfusion, a history of volume depletion, a 
history of reduced urine output, renal failure, known NSAID intolerance, treatment with 
angiotensin-converting enzyme inhibitors, sartanics and diuretics (30,42,43). In a 
retrospective review of 118 children who underwent ureteroneocystostomy, in which 50 
received narcotic analgesics postoperatively while another 68 received ketorolac 
postoperatively, there was no statistical difference between postoperative creatinine (0.68 
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and 0.65mg/dl) and haematocrit levels (33 and 34%) between the groups and no major 
complications (44). Besides the gastrointestinal and renal adverse reactions, other less 
common adverse effects reported after multiple doses of intramuscular ketorolac include 
somnolence, pain at the injection site, increased sweating, nausea, headache, dizziness, 
vomiting, pruritus and vasodilation (45). Ketorolac, unlike opioids, has not been associated 
with respiratory depression or tolerance (30, 45).  
 
Use of ketorolac in children 
Ketorolac has been reported to be an efficacious analgesic alternative to opioids in 
neonates, especially in conditions where there are high risks of respiratory depression. One 
study of a group of 18 preterm neonates with chronic lung disease examined the use of 
ketorolac to control postsurgical pain and pain from invasive procedures. It found that there 
was a significant reduction in the Neonatal Infant Pain Scale after the administration of 
1mg/kg of intravenous ketorolac as a bolus over 10 minutes, with total pain relief being 
achieved in 94.4% of cases. None of the neonates had significant changes in 
haematological, renal or hepatic indices after treatment or a systemic haemorrhage, gastric 
bleeding or haematuria. Meanwhile, the hourly urinary output remained constant and normal 
after the administration of the drug (46). In another study, ketorolac was safely used in 53 
neonates and infants after cardiac surgery and was not associated with any adverse 
haematologic or renal effects or clinically significant bleeding episodes (47). The blood urea 
nitrogen and serum creatinine levels increased from baseline at 48 hours of therapy in all 
infants but remained within normal limits (47).  
Ketorolac is effective in the treatment of moderate to severe pain in children and it is used 
for the treatment of several pain conditions, such as postoperative or chronic pain, renal 
colic pain, cancer pain and oral surgery pain and as an adjuvant therapy in anaesthesia and 
in patient-controlled analgesia (30). Ketorolac seems to be more useful as an analgesic than 
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as an anti-inflammatory agent, since the dose required to produce its anti-inflammatory 
effect is about 15 times higher than the dose required to produce its analgesic effect (30).  
Several studies have shown that ketorolac was better tolerated than morphine and other 
opioid drugs with similar effectiveness, in the treatment of moderate to severe postoperative 
pain, without producing opioid-related side effects, especially respiratory depression (48). 
Venous access in children presenting to an emergency department with pain requiring 
analgesia is not always easy. Pain relief needs to be provided reasonably quickly and the 
oral route is not ideal in the this setting for procedural sedation or analgesia, because there 
are often delays before the drug is absorbed in the small intestine and before the drug in 
plasma reaches its site of action. Alternative early analgesic administration delivery routes in 
young children, such as the intranasal route or the sublingual route, are available (49). A 
study by Neri et al (50) showed that a single dose of ketorolac administered through the 
sublingual route was as effective as sublingual tramadol for pain management in children 
with suspected fractures or dislocations and had fewer side effects. The pain reduction for 
sublingual ketorolac or sublingual tramadol given to children aged 4-17 years was similar to 
that described for intranasal fentanyl (49-51). Consequently, sublingual ketorolac may be a 
valid therapeutic alternative to intravenous injections for children requiring analgesia in the 
emergency department. Both sublingual and intranasal routes offer ease of administration, 
rapid systemic absorption and they avoid hepatic first-pass metabolism (49,50). Opioid-
related side effects, such as nausea, vomiting and respiratory depression, is avoided with 
ketorolac and other NSAIDs, while tramadol is associated with nausea and vomiting in a 
significant percentage of cases (49-51).  
Numerous adult studies (51-54) have compared the analgesic effects of ketorolac versus 
tramadol and other opioids in surgical settings, showing similar efficacy, reduced adverse 
effects and a morphine-sparing effect (52-55). In multiple-dose studies, ketorolac has 
showed an equivalent or superior profile when compared with either opioids or other NSAIDs 
in relieving moderate to severe pain (30). Ketorolac is also used as a therapy for renal colic 
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pain. In adults, providing 60mg of intramuscular ketorolac was better at reducing patients' 
renal colic pain than 150-100mg of intramuscular meperidine (56).  
Migraines are one of the most common causes of recurrent pain in children. Effective 
medication that is commonly used to treat acute migraine headache in the emergency 
department includes ketorolac, prochlorperazine and metoclopramide. A retrospective study 
showed that intravenous migraine therapy, with just ketorolac, ketorolac plus 
metoclopramide or prochlorperazine, just prochlorperazine or metoclopramide or just 
ondansetron, reduced posttraumatic headache pain scores for children within 14 days of a 
being treated for a mild traumatic brain injury in the emergency department (57). The 
treatment was successful in 86% of the 254 patients who were treated, defined as a 
reduction in their pain score of greater than or equal to 50%, with 52% experiencing a 
complete resolution of their headache. The medication combinations that were  most 
frequently given were ketorolac and metoclopramide or prochlorperazine (n = 152), with a 
high rate of treatment success (89%). Of the 55 patients who were just treated with 
ketorolac, 80% experienced treatment success (57). Another retrospective study showed the 
safety and efficacy of a standardised paediatric migraine practice guideline for reducing pain 
in children with migraine headaches in the emergency department (58). Children with a 
verbal numeric pain score of greater than six received 0.5mg/kg ketorolac (maximum 30mg), 
2mg/kg diphenhydramine (max 50mg), and either 0.2mg/kg metoclopramide (max 20mg) or 
0.1mg/kg prochlorperazine (max 10mg). After 40 minutes, another verbal numeric pain score 
was obtained, and, if there was no improvement, a repeat dose of metoclopramide or 
prochlorperazine was administered. A total of 533 patients were identified with a discharge 
diagnosis of migraine headache and 266 were enrolled. The mean initial verbal numeric pain 
score was 7.8 and the mean discharge verbal numeric pain score was 2.1, representing a 
73% reduction of pain (58).  
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Details of recommended ketorolac doses are given in Table 4.  
 
DISCUSSION 
Pain is a common symptom in emergency departments and ambulatory settings. 
Paracetamol and ibuprofen are useful for mild pain, but are not indicated for treating major 
pain. Tramadol and opioids are indicated for the treatment of moderate to severe pain and 
are licensed for use in children, but they are not devoid of possible adverse effects, such as 
nausea, vomiting and respiratory depression. The June 2013 EMA recommendations limiting 
codeine use, and the April 2017 warning by the FDA against using codeine and tramadol, 
have created a void in managing moderate pain in children. Ketorolac is only licensed for 
treating moderate to severe post-operatory pain in children. The major adverse effects of 
ketorolac are well known and a short-term use is indicated, particularly due to possible 
gastrointestinal involvement,.  
The issue we need to consider is if, in the light of the actual evidence, it is reasonable to limit 
the use of ketorolac to treating moderate to severe pain in the post-operative field or if it is 
possible to consider its short-term use in other settings as well. In our experience in the 
emergency department, which is in agreement with the evidence in the literature, the short-
term use of ketorolac, alone or in association with other drugs such paracetamol and 
opioids, appears to be safe and useful in many situations. 
CONCLUSION 
Our review of the literature showed that ketorolac had a good safety profile for short-term 
use in children. Gastrointestinal side effects were mainly reported when there was prolonged 
use or in cases of pre-existing conditions, such as gastritis. For short-term use, bleeding was 
mainly reported in adenotonsillectomies, while adverse renal effects appeared to be limited 
to patients with coexisting specific risk factors, such as hypoperfusion, volume depletion or 
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pre-existing kidney damage. More studies are needed in emergency departments and 
ambulatory settings to confirm the safety and efficacy of ketorolac for children.  
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Table 1. Comparative pharmacokinetic parameters of ketorolac after sublingual or 
intramuscular administration of 30 mg ketorolac tromethamine to 13 female healthy 
volunteers. Modified from Urizar et al (13) 
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Table 2: Ketorolac pharmacokinetics (modified from reference 24) 
 
 
  
ABSORPTION 
Bioavailability: 80-100% 
Onset: 10 min (intramuscular); 30-60 min (oral) 
Duration: 4-6 hours (analgesia) 
Peak serum time: 1-3 min (intravenous); 30-60 min (intramuscular); 
~1 hour (oral) 
Peak plasma concentration: varies with dose and route 
DISTRIBUTION 
Protein bound: >99% 
Volume distribution: ~13 L 
METABOLISM 
Metabolized in liver 
Metabolites: p-hydroxyketorolac, unidentified polar metabolites 
ELIMINATION 
Half-life: 2-6 hours 
Dialyzable: yes, with unknown effect 
Excretion: urine (91%), feces (6%) 
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a Potential effect. 
b Class effect of NSAIDs. 
ARB= angiotensin receptor blockers; FUR = furosemide; GI = gastrointestinal; KET = ketorolac; LIT = 
lithium; MET= methotrexate; pts = patients; SSRI = selective serotonin reuptake inhibitor; WAR= 
warfarin; 
 
Table 3: summary of pharmacological drug interactions with ketorolac (modified from 
reference 14) 
Concomitant drug  
or drug class 
Recommendations and effects 
when coadministered with ketorolac 
ACE inhibitors, ARB Consideration advised: increased risk of renal impairment 
(especially in volume-depleted pts)
a
, reduced antihypertensive 
effect of ACE inhibitors/ARB
a,b
 
Antiepileptic drugs (phenytoin, 
carbamazepine) 
Sporadic cases of seizures reported 
Aspirin  Not generally recommended: increase in adverse events 
a
; 
reduction in KET protein binding 
Diuretic drugs Patients should be observed for signs of renal failure: 
reduction in natriuretic effect of FUR and thiazides in some 
patients (data from clinical studies and postmarketing 
observations)
a
 
Lithium Patients should be observed for signs of LIT toxicity: reduction 
in renal LIT clearance, increase in LIT plasma levels 
b
 
Methotrexate Caution advised: increase MET toxicity;
a,b
 competitive 
inhibition of MET accumulation in kidney reported (data from 
animal studies)
b
 
Nondepolarizing muscle 
relaxants 
increased risk of apnoea (data from postmarketing 
observations)
a
 
Pentoxifylline Contraindicated: increased bleeding tendency 
Probenecid Contraindicated: reduction in oral KET clearance and volume 
of distribution, significant increase in oral KET plasma levels 
and terminal half-life 
Psychoactive drugs (fluoxetine, 
thiothixene, alprazolam) 
Hallucinations reported  
Salicylate reduction in KET protein binding (potential 2-fold increase in 
unbound KET plasma levels) [data from in vitro studies] 
SSRIs Caution advised: increased risk of GI bleeding 
Warfarin Synergistic effects on GI bleeding;
b
 slight reduction in WAR 
protein binding 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Age Route First administration Note 
6 months-16 
years 
Parenteral
* 
<2years 
0.25-0.5mg/kg 
(repeatable every 6-8 hours) 
possible continuous infusion continuing  
the administration of 0.83μg/h for 24 hours 
Licensed from 6 months; 
not licensed <6 months but 
efficacy and tolerability 
demonstrated in several 
studies 
≥2years 
0.5-1mg/kg (max 15mg) 
(repeatable every 6-8 hours) 
Intranasal
1 
0.5mg/kg  
(max 30mg but 15mg if weight <50kg) 
Not licensed. Clinical trial 
about intranasal 
administration with 
n°NCT02297906 in 
progress. Not yet available 
sufficient evidence about 
intranasal administration for 
the clinical use in children 
Oral/Sublingual
 
0.5mg/kg (max 20mg) 
(repeatable every 6 h) 
Not licensed but evidence 
about its safety are 
available in literature 
16-18 years Parenteral
*
 
<50kg 
15mg 
(repeatable every 6 hours; max 60mg/day) 
possible continuous infusion continuing  
the administration of 2.5mg/h for 24 hours) 
Licensed 
≥50 kg 
30mg 
(repeatable every 6hours; max 120mg/day) 
possible continuous infusion continuing  
Licensed 
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The minimum effective dose should be always preferred. The duration of the treatment should not be longer than 5 days 
*
Intramuscular route should not be preferred in order to minimize stressful procedures in childhood. 
1
Using MAD device 
2 
Alternatively, with MAD device can be administered 0.5mg/kg (max. 30 mg).                                                                     
 
 
Table 4: Ketorolac dosages in paediatric age (modified from references 6,30,48,49,50,51,59) 
 
 
 
the administration of 5mg/h for 24 hours 
Intranasal
2 
<50kg
 
15mg  
(repeatable every 6-8 hours; max 4 doses per day) 
Licensed 
≥50 kg 
30mg 
 
(repeatable every 6-8 hours; max 4 doses per day) 
Licensed 
Oral/Sublingual 
<50kg 
10mg 
(repeatable every 4-6 hours; max 40 mg/day) 
Licensed 
≥50 kg 
20mg  
(repeatable every 4-6 hours; max 40 mg/day) 
Licensed 
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